Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Rating Raised to “Sell” at Wall Street Zen

Wall Street Zen upgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA) from a strong sell rating to a sell rating in a research note released on Saturday morning,Wall Street Zen reports.

Several other analysts have also recently commented on VNDA. Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Thursday, October 15th. Oppenheimer began coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Vanda Pharmaceuticals in a research note on Monday, October 5th. Zacks Research cut shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 6th. Finally, B. Riley Financial restated a “buy” rating and issued a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a research report on Monday, August 10th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $13.50.

Vanda Pharmaceuticals Trading Down 6.4%

Shares of NASDAQ VNDA opened at $3.79 on Friday. The company has a quick ratio of 1.60, a current ratio of 1.54 and a debt-to-equity ratio of 0.01. The stock’s 50 day moving average price is $4.79 and its two-hundred day moving average price is $6.22. Vanda Pharmaceuticals has a 52-week low of $3.74 and a 52-week high of $9.94. The stock has a market capitalization of $229.14 million, a P/E ratio of -0.82 and a beta of 0.69.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, October 28th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.31. The firm had revenue of $69.81 million for the quarter, compared to analyst estimates of $69.20 million. Vanda Pharmaceuticals had a negative net margin of 119.87% and a negative return on equity of 62.70%. On average, analysts anticipate that Vanda Pharmaceuticals will post -2.68 earnings per share for the current fiscal year.

Institutional Trading of Vanda Pharmaceuticals

Several large investors have recently made changes to their positions in VNDA. State Street Corp grew its holdings in shares of Vanda Pharmaceuticals by 16.6% in the 2nd quarter. State Street Corp now owns 3,516,405 shares of the biopharmaceutical company’s stock worth $21,520,000 after purchasing an additional 500,843 shares during the last quarter. Syon Capital LLC bought a new position in Vanda Pharmaceuticals during the 2nd quarter valued at about $125,000. Hsbc Holdings PLC lifted its holdings in Vanda Pharmaceuticals by 144.5% during the 2nd quarter. Hsbc Holdings PLC now owns 94,988 shares of the biopharmaceutical company’s stock valued at $579,000 after purchasing an additional 56,133 shares during the last quarter. Wellington Management Group LLP bought a new position in Vanda Pharmaceuticals during the 2nd quarter valued at about $220,000. Finally, Jefferies Financial Group Inc. acquired a new position in Vanda Pharmaceuticals in the second quarter valued at about $749,000. Institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.